<p>箭头制药公司（NASDAQ:ARWR - 获取免费报告）的股票在覆盖该股票的十家研究公司中获得了 “适度买入” 的共识评级，Marketbeat Ratings 报告称。四位研究分析师对该股票给予了持有评级，六位分析师对该公司给予了买入评级。在过去一年中更新了对该股票覆盖的经纪公司中，平均十二个月的目标价格为 41.44 美元。</p>
<ul>
<li>想在生物技术领域获得多元化的上涨机会？查看 LABU</li>
</ul>
<p>多家股票研究分析师已对该公司发布了报告。加拿大皇家银行在 2 月 11 日的研究报告中重申了 “跑赢大盘” 的评级，并设定了 42.00 美元的目标价格。Chardan Capital 在 2 月 11 日的研究报告中重申了 “买入” 评级，并设定了 60.00 美元的目标价格。B. Riley 在 2 月 14 日的报告中重申了 “买入” 评级，并将目标价格下调至 38.00 美元（之前为 51.00 美元）。最后，HC Wainwright 在 2 月 12 日的研究报告中重申了 “买入” 评级，并设定了 80.00 美元的目标价格。</p>
<p><strong>阅读我们关于箭头制药的最新研究报告</strong></p>
<h2>箭头制药的内部活动</h2>
<p>在其他新闻中，首席执行官 Christopher Richard Anzalone 在 4 月 11 日的交易中出售了 50,800 股公司的股票。股票以平均价格 11.49 美元出售，总价值为 583,692.00 美元。出售后，首席执行官现在持有 3,921,255 股公司的股票，价值约为 45,055,219.95 美元。这代表了其持股比例的 1.28% 的减少。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站获取。在过去 90 天内，内部人士出售了 276,839 股公司股票，价值 4,054,176 美元。公司内部人士持有公司股票的 4.30%。</p>
<h2>对箭头制药的对冲基金看法</h2>
<p>机构投资者和对冲基金最近增加或减少了对该公司的持股。R Squared Ltd 在第四季度获得了箭头制药的新头寸，价值约为 38,000 美元。GAMMA Investing LLC 在第一季度将其在箭头制药的持股增加了 297.6%。GAMMA Investing LLC 现在持有 2,175 股该生物技术公司的股票，价值 28,000 美元，此前在上个季度购买了 1,628 股。GF Fund Management CO. LTD.在第四季度获得了箭头制药的新头寸，价值 49,000 美元。Van ECK Associates Corp 在第四季度将其在箭头制药的持股增加了 72.3%。Van ECK Associates Corp 现在持有 2,978 股该生物技术公司的股票，价值 56,000 美元，此前在上个季度购买了 1,250 股。最后，KBC Group NV 在第四季度将其在箭头制药的持股增加了 45.9%。KBC Group NV 现在持有 5,224 股该生物技术公司的股票，价值 98,000 美元，此前在上个季度购买了 1,644 股。目前 62.61% 的股票由机构投资者和对冲基金持有。</p>
<h2>箭头制药股票下跌 1.0%</h2>
<p>ARWR 周一开盘价为 11.24 美元。箭头制药的 12 个月低点为 9.57 美元，12 个月高点为 30.41 美元。该公司的 50 日移动平均线为 15.25 美元，200 日移动平均线为 18.59 美元。公司的债务与股本比率为 7.27，流动比率为 6.09，速动比率为 6.09。该股票的市值为 15.4 亿美元，市盈率为-2.17，贝塔值为 0.99。</p>
<p>箭头制药（NASDAQ:ARWR - 获取免费报告）最近在 2 月 10 日发布了季度财报。该生物技术公司报告季度每股收益为（1.39 美元），低于市场共识预期的（0.42 美元）差额为（0.97 美元）。研究分析师平均预计箭头制药在当前年度的每股收益将为-2.42 美元。</p>
<h2>关于箭头制药</h2>
<p>（获取免费报告）</p>
<p>箭头制药公司在美国开发用于治疗难治性疾病的药物。该公司的产品管线包括 Plozasiran，目前正在进行治疗高甘油三酯血症、混合性血脂异常和乳糜微粒血症综合征的 2b 期和 1 项 3 期临床试验；Zodasiran 正在进行治疗血脂异常和高甘油三酯血症的 2b 期临床试验；ARO-PNPLA3 正在进行治疗非酒精性脂肪性肝炎患者的 1 期临床试验；ARO-RAGE 正在进行治疗炎症性肺部疾病的 1/2a 期临床试验；ARO-MUC5AC 正在进行治疗粘液阻塞性肺病的 1/2a 期临床试验。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比箭头制药更好</li>
<li>股票拆分意味着什么？</li>
<li>以 60% 以上的上涨空间，Lovesac 有很多值得喜爱的地方</li>
<li>股票行业对成功投资的重要性是什么？</li>
<li>J.B. Hunt Transport 过度修正，成为买入机会</li>
<li>投资于便士股票需要了解什么</li>
<li>AppLovin：创纪录的利润能否克服市场怀疑？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在箭头制药吗？</h2>
<p>在考虑箭头制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而箭头制药并不在名单上。</p>
<p>虽然箭头制药目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

箭头制药

<p>Arrowhead Pharmaceuticals, Inc.（纳斯达克代码：ARWR）获得了十家研究公司的共识评级为 “适度买入”。四位分析师给予持有评级，而六位分析师则给予买入评级。平均目标价为 41.44 美元。最近的报告包括加拿大皇家银行的 42 美元目标和 Chardan Capital 的 60 美元目标。该股票目前下跌 1.0%，交易价格为 11.24 美元，12 个月的价格区间为 9.57 美元至 30.41 美元。公司报告的季度每股收益为（1.39 美元），低于预期（0.97 美元）</p>

<p>Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have earned a consensus rating of &#34;Moderate Buy&#34; from the ten research firms that are covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $41.44.</p>
<div class="lb-trans"><p>箭头制药公司（NASDAQ:ARWR - 获取免费报告）的股票在覆盖该股票的十家研究公司中获得了 “适度买入” 的共识评级，Marketbeat Ratings 报告称。四位研究分析师对该股票给予了持有评级，六位分析师对该公司给予了买入评级。在过去一年中更新了对该股票覆盖的经纪公司中，平均十二个月的目标价格为 41.44 美元。</p>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想在生物技术领域获得多元化的上涨机会？查看 LABU</li>
</ul>
</div><p>A number of equities research analysts have issued reports on the company. Royal Bank of Canada reissued an &#34;outperform&#34; rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Chardan Capital reissued a &#34;buy&#34; rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. B. Riley restated a &#34;buy&#34; rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Finally, HC Wainwright reiterated a &#34;buy&#34; rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th.</p>
<div class="lb-trans"><p>多家股票研究分析师已对该公司发布了报告。加拿大皇家银行在 2 月 11 日的研究报告中重申了 “跑赢大盘” 的评级，并设定了 42.00 美元的目标价格。Chardan Capital 在 2 月 11 日的研究报告中重申了 “买入” 评级，并设定了 60.00 美元的目标价格。B. Riley 在 2 月 14 日的报告中重申了 “买入” 评级，并将目标价格下调至 38.00 美元（之前为 51.00 美元）。最后，HC Wainwright 在 2 月 12 日的研究报告中重申了 “买入” 评级，并设定了 80.00 美元的目标价格。</p>
</div><p><strong>Read Our Latest Research Report on Arrowhead Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于箭头制药的最新研究报告</strong></p>
</div><h2>Insider Activity at Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>箭头制药的内部活动</h2>
</div><p>In other news, CEO Christopher Richard Anzalone sold 50,800 shares of the company's stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $11.49, for a total value of $583,692.00. Following the sale, the chief executive officer now owns 3,921,255 shares of the company's stock, valued at approximately $45,055,219.95. This represents a 1.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 276,839 shares of company stock worth $4,054,176. Company insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Christopher Richard Anzalone 在 4 月 11 日的交易中出售了 50,800 股公司的股票。股票以平均价格 11.49 美元出售，总价值为 583,692.00 美元。出售后，首席执行官现在持有 3,921,255 股公司的股票，价值约为 45,055,219.95 美元。这代表了其持股比例的 1.28% 的减少。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站获取。在过去 90 天内，内部人士出售了 276,839 股公司股票，价值 4,054,176 美元。公司内部人士持有公司股票的 4.30%。</p>
</div><h2>Hedge Funds Weigh In On Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>对箭头制药的对冲基金看法</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth approximately $38,000. GAMMA Investing LLC raised its position in Arrowhead Pharmaceuticals by 297.6% in the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,628 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Arrowhead Pharmaceuticals in the fourth quarter worth $49,000. Van ECK Associates Corp grew its holdings in shares of Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 1,250 shares during the last quarter. Finally, KBC Group NV increased its stake in shares of Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after buying an additional 1,644 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近增加或减少了对该公司的持股。R Squared Ltd 在第四季度获得了箭头制药的新头寸，价值约为 38,000 美元。GAMMA Investing LLC 在第一季度将其在箭头制药的持股增加了 297.6%。GAMMA Investing LLC 现在持有 2,175 股该生物技术公司的股票，价值 28,000 美元，此前在上个季度购买了 1,628 股。GF Fund Management CO. LTD.在第四季度获得了箭头制药的新头寸，价值 49,000 美元。Van ECK Associates Corp 在第四季度将其在箭头制药的持股增加了 72.3%。Van ECK Associates Corp 现在持有 2,978 股该生物技术公司的股票，价值 56,000 美元，此前在上个季度购买了 1,250 股。最后，KBC Group NV 在第四季度将其在箭头制药的持股增加了 45.9%。KBC Group NV 现在持有 5,224 股该生物技术公司的股票，价值 98,000 美元，此前在上个季度购买了 1,644 股。目前 62.61% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Arrowhead Pharmaceuticals Stock Down 1.0 %</h2>
<div class="lb-trans"><h2>箭头制药股票下跌 1.0%</h2>
</div><p>ARWR opened at $11.24 on Monday. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $30.41. The business has a 50-day moving average of $15.25 and a two-hundred day moving average of $18.59. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -2.17 and a beta of 0.99.</p>
<div class="lb-trans"><p>ARWR 周一开盘价为 11.24 美元。箭头制药的 12 个月低点为 9.57 美元，12 个月高点为 30.41 美元。该公司的 50 日移动平均线为 15.25 美元，200 日移动平均线为 18.59 美元。公司的债务与股本比率为 7.27，流动比率为 6.09，速动比率为 6.09。该股票的市值为 15.4 亿美元，市盈率为-2.17，贝塔值为 0.99。</p>
</div><p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, research analysts expect that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current year.</p>
<div class="lb-trans"><p>箭头制药（NASDAQ:ARWR - 获取免费报告）最近在 2 月 10 日发布了季度财报。该生物技术公司报告季度每股收益为（1.39 美元），低于市场共识预期的（0.42 美元）差额为（0.97 美元）。研究分析师平均预计箭头制药在当前年度的每股收益将为-2.42 美元。</p>
</div><h2>About Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于箭头制药</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.</p>
<div class="lb-trans"><p>箭头制药公司在美国开发用于治疗难治性疾病的药物。该公司的产品管线包括 Plozasiran，目前正在进行治疗高甘油三酯血症、混合性血脂异常和乳糜微粒血症综合征的 2b 期和 1 项 3 期临床试验；Zodasiran 正在进行治疗血脂异常和高甘油三酯血症的 2b 期临床试验；ARO-PNPLA3 正在进行治疗非酒精性脂肪性肝炎患者的 1 期临床试验；ARO-RAGE 正在进行治疗炎症性肺部疾病的 1/2a 期临床试验；ARO-MUC5AC 正在进行治疗粘液阻塞性肺病的 1/2a 期临床试验。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>What Does a Stock Split Mean?</li>
<li>With a 60%+ Upside, There’s Plenty to Love About Lovesac</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>J.B. Hunt Transport Overcorrects Into a Buying Opportunity</li>
<li>What to Know About Investing in Penny Stocks</li>
<li>AppLovin: Can Record Profits Overcome Market Skepticism?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比箭头制药更好</li>
<li>股票拆分意味着什么？</li>
<li>以 60% 以上的上涨空间，Lovesac 有很多值得喜爱的地方</li>
<li>股票行业对成功投资的重要性是什么？</li>
<li>J.B. Hunt Transport 过度修正，成为买入机会</li>
<li>投资于便士股票需要了解什么</li>
<li>AppLovin：创纪录的利润能否克服市场怀疑？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ARWR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在箭头制药吗？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑箭头制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而箭头制药并不在名单上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然箭头制药目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

箭头制药公司（NASDAQ: ARWR）被券商给予 “适度买入” 的平均评级